Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Asia Healthcare Industry Digest.
Press releases published on April 23, 2025
Pineal XT Reviews (WARNING) Is It Safe And Worth Trying? Understanding Its Natural Ingredients And Benefits!
GlobeNewswire
·
April 23, 2025
ALBANY, N.Y., April 23, 2025 (GLOBE NEWSWIRE) -- Pineal XT is a natural dietary capsule developed and designed to support cognitive functions. It blends in scientifically proven ingredients to enhance brain power, improve mood, stimulate the pineal gland, …
Prime Biome Reviews (We Tried It for 115 Days) Here’s Our Month-by-Month Review, Unexpected Results, And Benefits!
GlobeNewswire
·
April 23, 2025
ALBANY, N.Y., April 23, 2025 (GLOBE NEWSWIRE) -- Prime Biome is a dietary supplement designed to support skin and gut health by achieving microbial equilibrium in the body. It is loaded with probiotics for clear skin and anti-aging vitamins that can combat …
John Flack Appointed CFO of Advanced Medical Pricing Solutions
GlobeNewswire
·
April 23, 2025
PHOENIX, April 23, 2025 (GLOBE NEWSWIRE) -- Advanced Medical Pricing Solutions (“AMPS”), a diversified healthcare technology company supporting transparent, affordable medical and prescription benefits, announced today the appointment of John A. Flack II …
Liquid Biopsy in Cancer Diagnostics Market to Grow at a CAGR of ~17% by 2032 with Advancements in Non-Invasive Testing | DelveInsight
GlobeNewswire
·
April 23, 2025
New York, USA, April 23, 2025 (GLOBE NEWSWIRE) -- Liquid Biopsy in Cancer Diagnostics Market to Grow at a CAGR of ~17% by 2032 with Advancements in Non-Invasive Testing | DelveInsight The liquid biopsy market size in cancer diagnostics is experiencing …
AB Science announces that EMA granted orphan drug status to AB8939 for the treatment of acute myeloid leukemia
GlobeNewswire
·
April 23, 2025
PRESS RELEASE EUROPEAN MEDICINES AGENCY (EMA) HAS GRANTED ORPHAN DRUG DESIGNATION IN THE EUROPEAN UNION FOR AB8939 IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA Paris, April 23, 2025, 6.45pm CET AB Science SA (Euronext - FR0010557264 - AB) announces today …
La molécule AB8939 obtient la désignation de médicament orphelin auprès de l'EMA dans le traitement de la leucémie myéloïde aigue
GlobeNewswire
·
April 23, 2025
COMMUNIQUE DE PRESSE LA MOLECULE AB8939 OBTIENT LA DESIGNATION DE MEDICAMENT ORPHELIN DANS L’UNION EUROPEENNE AUPRES DE L’AGENCE EUROPEENNE DES MEDICAMENTS (EMA) DANS LE TRAITEMENT DE LA LEUCEMIE MYELOÏDE AIGUE Paris, 23 avril 2025, 18h45 AB Science SA ( …
MJH Life Sciences® and the American College of Cardiology collaborate to advance pharmacists’ role in cardiovascular care through education and clinical collaboration
GlobeNewswire
·
April 23, 2025
CRANBURY, N.J., April 23, 2025 (GLOBE NEWSWIRE) -- MJH Life Sciences® announces a Strategic Alliance Partnership (SAP) between the American College of Cardiology (ACC) and two MJH premier brands, Pharmacy Times® (PT) and Pharmacy Times Continuing Education …
OSE Immunotherapeutics Highlights Abstracts Selected for Presentation at ASCO 2025
GlobeNewswire
·
April 23, 2025
OSE Immunotherapeutics Highlights Abstracts Selected for Presentation at ASCO 2025 Featuring proprietary asset Tedopi® and two partnered SIRPα inhibitor assets with Boehringer Ingelheim NANTES, France – April 23, 2025, 6:00 p.m. CET - OSE …
OSE Immunotherapeutics annonce la sélection de plusieurs abstracts pour présentation à l’ASCO 2025
GlobeNewswire
·
April 23, 2025
OSE Immunotherapeutics annonce la sélection de plusieurs abstracts pour présentation à l’ASCO 2025 Présentations sur l’actif propriétaire Tedopi® et sur deux inhibiteurs de SIRPα développés en partenariat avec Boehringer Ingelheim NANTES, France, 23 avril …
Artax Biopharma to present Phase 2a data on Nck modulator AX-158, establishing novel mechanism of action in autoimmune disease at the 2025 SID Annual Meeting
GlobeNewswire
·
April 23, 2025
Late breaker abstract presentation to showcase clinical validation of first-in-class oral small molecule AX-158 in cohort of patients with psoriasis Full dataset to expand on previously announced topline results, reinforcing the potential of Nck modulation …
AAPA 2025 Opening General Session to Explore How Technology Is Reshaping Patient Care
GlobeNewswire
·
April 23, 2025
Alexandria, Va., April 23, 2025 (GLOBE NEWSWIRE) -- The American Academy of Physician Associates (AAPA) will explore how innovation is helping medical providers address today’s top healthcare issues and improve patient outcomes during AAPA 2025’s opening …
Arvinas Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire
·
April 23, 2025
– Oral presentation will serve as first presentation of detailed results from the Phase 3 VERITAC-2 clinical trial – NEW HAVEN, Conn., April 23, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that data from the global Phase 3 VERITAC …
ImCheck Announces Oral Presentation of Updated ICT01 Efficacy Data in First-line AML at the ASCO Annual Meeting 2025
GlobeNewswire
·
April 23, 2025
ImCheck Announces Oral Presentation of Updated ICT01 Efficacy Data in First-line AML at the ASCO Annual Meeting 2025 Marseille, France, April 23, 2025 10:00 a.m. ET / 4:00 p.m. CET– ImCheck Therapeutics announced today an oral presentation at the upcoming …
Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire
·
April 23, 2025
- Oral presentation at ASCO to highlight topline Phase 2 data of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) in first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) CHICAGO and FORT WORTH, Texas, April 23, 2025 ( …
SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire
·
April 23, 2025
NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, …
PDS Biotech Announces Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire
·
April 23, 2025
PRINCETON, N.J., April 23, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced …
Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, at ASCO 2025
GlobeNewswire
·
April 23, 2025
CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that results from the REZILIENT1 study of zipalertinib …
Mersana Therapeutics Announces Upcoming Emi-Le Oral and Poster Presentations at ASCO 2025 Annual Meeting
GlobeNewswire
·
April 23, 2025
CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of …
Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire
·
April 23, 2025
SOUTH SAN FRANCISCO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today …
Update: Dental Implants and Prosthetics market to grow at a CAGR of 5.4% during the forecast period (2025 – 2030): Wissen Research
GlobeNewswire
·
April 23, 2025
Sheridan, April 23, 2025 (GLOBE NEWSWIRE) -- According to the latest market report published by Wissen Research, the global dental implants and prosthetics market is valued at 12.1 billion in 2024. Furthermore, the market is expected to grow at a CAGR of 5 …